OBJECTIVES: Medication, surgery, and other conventional therapies are used to manage symptoms and delay progression of chronic obstructive pulmonary disease (COPD), with considerable potential for adverse events. Complementary therapies are promising for symptom management with potentially less risk for negative consequences compared to conventional therapies. The purpose of this study is to explore patient interest in using and paying for a complementary therapy for COPD, an exercise table modeled after the polio-era rocking beds, designed for daily at-home use to improve breathing. METHODS: An exploratory cross-sectional survey from a convenience sample of 424 adults with COPD in the US was conducted from March to June 2016. RESULTS: Participants were predominantly female (n=256, 60.4%), Caucasian (n=357, 84.2%); age 62.1 years (mean); household income < $25,000 USD (n=171,40.3%); and were taking 3 or more COPD medications (n=345, 81.4%). Nearly one-third (n=135, 31.8%) would consider using the exercise table; 42.5% (n=180) were not interested or undecided. Among those interested, the most common reasons were: interest in new products (58.5%); preference for home therapies (49.0%); and interest in alternative therapies (38.5%). The most common reasons among not interested/undecided were: appeared too expensive (49.4%); would only use with doctor's permission (34.4%); and space constraints (31.7%). Assuming effectiveness, 57.3% (n=243) would like to try the device and 164 (67.5%) would use only if free of charge. Interested participants were willing to pay $513.52 USD (mean) for this device. More participants interested in this complementary therapy had severe or very severe COPD (78/135, 57.8% vs. 11/38, 28.9%) with a longer duration (7.6 vs. 5.7 years) compared to those who were not interested. CONCLUSIONS: Individuals with COPD, particularly with advanced disease, are interested in complementary therapies. Doctor’s approval and cost are important; therefore, research on complementary therapies is needed to inform evidence-based healthcare and offer new, potentially safer, and affordable options for COPD management.